September 25, 2026
Read time: ~4 minutes.

The U.S. illicit drug landscape is constantly changing shape.  One of the clearest trends of the last several years is the spread of xylazine, a veterinary sedative better known on the street as “tranq,” into the fentanyl supply. What started as a regional adulterant concentrated in parts of the Northeast has become a nationwide detection challenge.

For harm reduction programs, treatment centers, correctional facilities, law enforcement, and first responders, knowing whether a sample contains xylazine is becoming more essential to safe response. Here’s what’s driving the trend, why it matters clinically, and how rapid residue testing fits into the response.

What Is Xylazine, and Why Is It Showing Up in Fentanyl?

Xylazine is a non-opioid sedative approved by the FDA for veterinary use only; there is no approved human application. It is a central nervous system depressant that slows breathing, heart rate, and blood pressure. Traffickers add it to fentanyl because it extends and intensifies the drug’s sedating effects and stretches product volume, thereby increasing profit margins.

The danger is twofold. First, xylazine is not an opioid, so naloxone (Narcan) does not reverse its effects. A person exposed to a fentanyl-xylazine mixture may not fully respond to standard overdose reversal, although naloxone is still administered due to the likely opioid presence. Second, repeated exposure is associated with severe, necrotic skin wounds that can appear even in people who don’t inject the drug, sometimes leading to amputation.

The Numbers Behind the Trend

The data tells a consistent story of expansion:

• The DEA has reported seizing fentanyl-xylazine mixtures in 48 of 50 states.   Laboratory testing found xylazine in roughly 23% of seized fentanyl powder and 7% of seized fentanyl pills in 2022.
• CDC surveillance found that the share of illicitly manufactured fentanyl overdose deaths involving xylazine rose sharply between January 2019 and June 2022, climbing from 2.9% to 10.9% of cases; an increase of over 200%. CDC and DEA both note the true prevalence of xylazine is likely underestimated due to varying testing practices by state and toxicology panels not commonly including the drug
• A 2026 JAMA Network Open study of more than 42,000 fentanyl-positive urine specimen samples collected between March 2023 and September 2025 found xylazine present in 17% of samples overall.  Detection rose over the study period in both the Eastern and Western U.S., including a jump from essentially 0% to 13% in the West, a region that historically saw far less xylazine than the East Coast.

 The pattern is unmistakable: fentanyl is increasingly cut with non-opioid sedatives that standard drug panels will not detect, and the mix of adulterants is shifting from month to month.

Why Standard Testing Isn’t Enough

Most opioid immunoassay panels are designed to detect opiates and synthetic opioids like fentanyl, not sedatives like xylazine. That means a sample, pill, or surface residue can test negative for adulteration on a routine panel while still containing a substance that will blunt naloxone’s effectiveness and put a person at serious risk. Programs that perform routine drug testing, wound care intake, treatment admissions, or law enforcement evidence screening, dedicated xylazine detection has become a necessary complement to fentanyl testing rather than an optional add-on.

How Healgen’s Fentanyl/Xylazine Residue Test Helps

Healgen’s Fentanyl/Xylazine Residue Test is designed for exactly the detection gap that currently exists. It’s a rapid, qualitative screening test that detects fentanyl and/or xylazine residue (dried liquid or powder) on surfaces, including the outer surface of pills, thus eliminating the need for a biological specimen sample. This makes the Healgen’s Fentanyl/Xylazine Residue Test well suited to routine drug testing programs, harm reduction outreach, forensic and law enforcement screening, and facility intake procedures, where speed and simplicity matter.

Key features include:

• Two formats to fit your workflow: available as both a lateral-flow strip and a cassette. Programs can choose the format that best matches their collection and interpretation process.
• Fast results: the strip delivers results in 3–10 minutes and the cassette in 5–10 minutes, with results not intended to be read after 1 hour.
• Sensitive cutoffs: fentanyl detection at a 5 ng/mL cutoff and xylazine detection at a 50 ng/mL cutoff.
• Simple, visual interpretation: no specialized equipment or training required to collect a sample and read a result.
• Flexible ordering: available as standalone Fentanyl Residue Test kits, standalone Xylazine Residue Test kits, or a combined Fentanyl/Xylazine Residue Test cassette that screens for both in a single device. Each in kits containing 20 tests.

As the illicit drug supply continues to shift toward new sedative adulterants, it is important to have a fast, reliable way to screen for xylazine alongside fentanyl.  Healgen’s Fentanyl/Xylazine Residue Test gives programs a critical early warning tool that supports safer response decisions before a situation becomes an emergency.

The Bottom Line

Xylazine’s spread through the fentanyl supply is no longer a regional anomaly; it is a nationwide trend backed by DEA seizure data, CDC mortality surveillance, and peer-reviewed toxicology research. Opioid panels are not designed to detect sedatives, which is why dedicated xylazine residue testing has become a practical necessity for harm reduction programs, treatment providers, and public safety agencies alike.

Explore Healgen’s Fentanyl/Xylazine Residue Test to see which strip or cassette format fits your program, or contact the Healgen team to talk through ordering and implementation.